European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 33, Issue 3, Pages 276-287
Publisher
Elsevier BV
Online
2021-12-01
DOI
10.1016/j.annonc.2021.11.013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
- (2021) Tamara L. Lotan et al. MODERN PATHOLOGY
- Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
- (2021) Pascal Pujol et al. EUROPEAN JOURNAL OF CANCER
- Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
- (2021) Eric Pujade-Lauraine et al. GYNECOLOGIC ONCOLOGY
- Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions
- (2021) Chiara Guglielmi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
- (2020) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D
- (2020) Xin Yang et al. JNCI-Journal of the National Cancer Institute
- Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
- (2020) Hisamitsu Takaya et al. Scientific Reports
- Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
- (2020) Michele Bartoletti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ctDNA from ascites as an alternative to tumor sampling for HRD (homologous recombination deficiency) testing in ovarian cancer (OC).
- (2020) Alexandra Leary et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of initiating in-office germline testing in safety net clinic patients with epithelial ovarian cancer.
- (2020) Scott Jordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular assessment of mismatch repair deficiency in Lynch-associated ovarian cancers using next-generation sequencing (NGS) panel.
- (2020) Rachel Soyoun Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
- (2020) Ilary Ruscito et al. CANCER TREATMENT REVIEWS
- The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
- (2020) Yingzhu Yang et al. World Journal of Surgical Oncology
- Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
- (2020) Dominik Glodzik et al. Nature Communications
- ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
- (2020) R.E. Miller et al. ANNALS OF ONCOLOGY
- DNA mismatch repair-dependent DNA damage responses and cancer
- (2020) Robbert Ijsselsteijn et al. DNA REPAIR
- Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
- (2020) Beyhan Ataseven et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Assessment of mismatch repair deficiency in ovarian cancer
- (2020) Emma J Crosbie et al. JOURNAL OF MEDICAL GENETICS
- Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
- (2020) Amos Stemmer et al. Cancers
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.
- (2019) Mansoor Raza Mirza et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.
- (2019) Adriaan Vanderstichele et al. JOURNAL OF CLINICAL ONCOLOGY
- Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
- (2019) Jan Hauke et al. JOURNAL OF MEDICAL GENETICS
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- (2019) Mansoor Raza Mirza et al. LANCET ONCOLOGY
- Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients
- (2019) Kentaro Sugino et al. Scientific Reports
- Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
- (2019) Xin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer
- (2018) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
- (2018) Euan A. Stronach et al. MOLECULAR CANCER RESEARCH
- Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
- (2018) Jai N. Patel et al. BRITISH JOURNAL OF CANCER
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell Origins of High-Grade Serous Ovarian Cancer
- (2018) Jaeyeon Kim et al. Cancers
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
- (2017) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
- (2017) Brian A. Dougherty et al. Oncotarget
- Epidemiology of ovarian cancer: a review
- (2017) Reid Brett M. et al. Cancer Biology & Medicine
- Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
- (2017) Philipp Harter et al. PLoS One
- BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
- (2016) M. Moschetta et al. ANNALS OF ONCOLOGY
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
- (2016) Hubert Fleury et al. Oncotarget
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
- (2016) Angela George et al. Scientific Reports
- Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population
- (2015) Honglin Song et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
- (2015) Susan J. Ramus et al. JNCI-Journal of the National Cancer Institute
- Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
- (2015) Susan J. Ramus et al. JNCI-Journal of the National Cancer Institute
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- Hereditary ovarian cancer: Beyond the usual suspects
- (2012) Kathryn P. Pennington et al. GYNECOLOGIC ONCOLOGY
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- XIAP Is a Predictor of Cisplatin-Based Chemotherapy Response and Prognosis for Patients with Advanced Head and Neck Cancer
- (2012) Xi-Hu Yang et al. PLoS One
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Germline mutations in RAD51D confer susceptibility to ovarian cancer
- (2011) Chey Loveday et al. NATURE GENETICS
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
- (2011) T. Walsh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation